Gastric Cancer
1,822
324
412
673
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
159 trials with published results (9%)
Research Maturity
673 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.4%
117 terminated out of 1822 trials
85.2%
-1.4% vs benchmark
11%
202 trials in Phase 3/4
24%
159 of 673 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 673 completed trials
Clinical Trials (1822)
Distance-Based Exercise to Preserve Function and Prevent Disability
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Nutrition Intervention Trials in Linxian Follow-up Study
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
IKS014 in Advanced Solid Tumors That Express HER2
RCT of Mobile Apps & FitBit v. Usual Care
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors